{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T05:00:58Z","timestamp":1789275658253,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81060050"],"award-info":[{"award-number":["81060050"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81660032"],"award-info":[{"award-number":["81660032"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015310","name":"Natural Science Foundation of Xinjiang","doi-asserted-by":"publisher","award":["2022D01C238"],"award-info":[{"award-number":["2022D01C238"]}],"id":[{"id":"10.13039\/501100015310","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jtct.2023.02.005","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T18:14:27Z","timestamp":1676052867000},"page":"331.e1-331.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Unique Reduced-Intensity Conditioning Haploidentical Peripheral Blood Stem Cell Transplantation Protocol for Patients with Hematologic Malignancy"],"prefix":"10.1016","volume":"29","author":[{"given":"Jianli","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyan","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulibadanmu","family":"Aizezi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianlin","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maliya","family":"Muhashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxia","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linglu","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadiya","family":"Abulaiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nannan","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2023.02.005_bib0001","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.bbmt.2015.06.008","article-title":"HLA-haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide after busulfan-containing reduced-intensity conditioning","volume":"21","author":"Sugita","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.02.005_bib0002","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.bbmt.2017.05.003","article-title":"Sources of hematopoietic stem and progenitor cells and methods to optimize yields for clinical cell therapy","volume":"23","author":"Panch","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.02.005_bib0003","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.2017.72.8428","article-title":"Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell-replete haploidentical donor transplantation using post-transplant cyclophosphamide","volume":"35","author":"Bashey","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.02.005_bib0004","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1200\/JCO.2005.09.020","article-title":"Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials","volume":"23","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.02.005_bib0005","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.critrevonc.2014.12.007","article-title":"Comparison of bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for hematological malignancies in adults - a systematic review and meta-analysis","volume":"94","author":"Holtick","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jtct.2023.02.005_bib0006","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2010-08-302109","article-title":"Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria","volume":"117","author":"Flowers","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.02.005_bib0007","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s12185-015-1782-4","article-title":"Therapeutic benefits targeting B-cells in chronic graft-versus-host disease","volume":"101","author":"Nakasone","year":"2015","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2023.02.005_bib0008","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00277-013-1957-0","article-title":"Serum albumin level predicts survival of patients with gastrointestinal acute graft-versus-host disease after allogeneic stem cell transplantation","volume":"93","author":"Ayuk","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2023.02.005_bib0009","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/bmt.2013.168","article-title":"Favorable impact of pre-transplant ATG on outcomes of reduced-intensity hematopoietic cell transplants from partially mismatched unrelated donors","volume":"49","author":"Langston","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.02.005_bib0010","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s12185-013-1449-y","article-title":"Reduced-intensity conditioning regimen with low-dose ATG-F for unrelated bone marrow transplant is associated with lower non-relapse mortality than a regimen with low-dose TBI: a single-center retrospective analysis of 103 cases","volume":"98","author":"Fuji","year":"2013","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2023.02.005_bib0011","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1182\/blood.V84.11.3948.bloodjournal84113948","article-title":"Successful engraftment of T-cell-depleted haploidentical \"three-loci\" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum","volume":"84","author":"Aversa","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.02.005_bib0012","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1056\/NEJM199810223391702","article-title":"Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype","volume":"339","author":"Aversa","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.02.005_bib0013","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1200\/JCO.2005.09.117","article-title":"Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse","volume":"23","author":"Aversa","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.02.005_bib0014","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/bmt.2014.108","article-title":"Haploidentical transplantation using G-CSF-mobilized T-cell replete PBSCs and post-transplantation CY after non-myeloablative conditioning is safe and is associated with favorable outcomes","volume":"49","author":"Bhamidipati","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.02.005_bib0015","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.bbmt.2014.03.003","article-title":"Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning","volume":"20","author":"Raj","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.02.005_bib0016","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.bbmt.2014.02.001","article-title":"Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide","volume":"20","author":"Castagna","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.02.005_bib0017","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1038\/s41409-019-0500-x","article-title":"Peripheral blood stem cell for haploidentical transplantation with post-transplant high dose cyclophosphamide: detailed analysis of 181 consecutive patients","volume":"54","author":"Granata","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.02.005_bib0018","first-page":"293","article-title":"Use of an anti-interleukin-2 receptor monoclonal antibody for GVHD prophylaxis in unrelated donor BMT","volume":"11","author":"Belanger","year":"1993","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.02.005_bib0019","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1097\/00007890-199712270-00012","article-title":"Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts","volume":"64","author":"Kovarik","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.jtct.2023.02.005_bib0020","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1016\/j.transproceed.2012.09.109","article-title":"Initial immunosuppression with or without basiliximab: a comparative study","volume":"44","author":"Mart\u00edn-Mateos","year":"2012","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jtct.2023.02.005_bib0021","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.trim.2016.08.009","article-title":"T cell costimulation blockade for hyperacute steroid refractory graft versus-host disease in children undergoing haploidentical transplantation","volume":"39","author":"Jaiswal","year":"2016","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.jtct.2023.02.005_bib0022","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13045-018-0564-x","article-title":"The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China: recommendations from the Chinese Society of Hematology","volume":"11","author":"Xu","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jtct.2023.02.005_bib0023","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1182\/blood-2007-06-096966","article-title":"Hematopoietic cell transplantation-specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences","volume":"110","author":"Sorror","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.02.005_bib0024","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.02.005_bib0025","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00428-015-1803-y","article-title":"Consensus diagnostic histopathological criteria for acute gastrointestinal graft versus host disease improve interobserver reproducibility","volume":"467","author":"Kreft","year":"2015","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jtct.2023.02.005_bib0026","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/bmt.2016.215","article-title":"Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from haploidentical donors after non-ablative conditioning: a matched-pair analysis","volume":"51","author":"O'Donnell","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.02.005_bib0027","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/ajh.25826","volume":"95","author":"Maffini","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2023.02.005_bib0028","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1016\/j.bbmt.2018.07.008","article-title":"Reduced-Intensity conditioning and dual T lymphocyte suppression with antithymocyte globulin and post-transplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical hematopoietic stem cell transplants for hematological malignancies","volume":"24","author":"Law","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.02.005_bib0029","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12916-019-1393-7","article-title":"Two dose levels of rabbit antithymocyte globulin as graft-versus-host disease prophylaxis in haploidentical stem cell transplantation: a multicenter randomized study","volume":"17","author":"Lin","year":"2019","journal-title":"BMC Med"},{"key":"10.1016\/j.jtct.2023.02.005_bib0030","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s00277-020-04014-5","article-title":"Comparison of ATG-thymoglobulin with ATG-fresenius for Epstein-Barr virus infections and graft-versus-host-disease in patients with hematological malignances after haploidentical hematopoietic stem cell transplantation: a single-center experience","volume":"99","author":"Zhou","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2023.02.005_bib0031","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/bmt.2013.191","article-title":"Influence of two different doses of antithymocyte globulin in patients with standard-risk disease following haploidentical transplantation: a randomized trial","volume":"49","author":"Wang","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.02.005_bib0032","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1002\/cncr.30540","article-title":"Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: long-term outcomes of a prospective randomized trial","volume":"123","author":"Chang","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2023.02.005_bib0033","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1200\/JCO.2015.63.8817","article-title":"Controlled, randomized, open-label trial of risk-stratified corticosteroid prevention of acute graft-versus-host disease after haploidentical transplantation","volume":"34","author":"Chang","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.02.005_bib0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcmd.2007.06.030","article-title":"From 'megadose' haploidentical hematopoietic stem cell transplants in acute leukemia to tolerance induction in organ transplantation","volume":"40","author":"Reisner","year":"2008","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.jtct.2023.02.005_bib0035","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1097\/00007890-199805270-00017","article-title":"Tolerance induction by \u201cmegadose\u201d hematopoietic transplants: donor-type human CD34 stem cells induce potent specific reduction of host anti-donor cytotoxic T lymphocyte precursors in mixed lymphocyte culture","volume":"65","author":"Rachamim","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.jtct.2023.02.005_bib0036","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1016\/j.bbmt.2020.07.034","article-title":"Impact of anti-CMV IgG titers and CD34 count prior to hematopoietic stem cell transplantation from alternative donors on CMV reactivation","volume":"26","author":"Arcuri","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.02.005_bib0037","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.bbmt.2017.10.043","article-title":"Impact of a low CD34+ cell dose on allogeneic peripheral blood stem cell transplantation","volume":"24","author":"Yamamoto","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.02.005_bib0038","doi-asserted-by":"crossref","first-page":"27","DOI":"10.5045\/br.2020.55.1.27","article-title":"Similar transplant outcomes between haploidentical and unrelated donors after reduced-intensity conditioning with busulfan, fludarabine, and anti-thymocyte globulin in patients with acute leukemia or myelodysplastic syndrome","volume":"55","author":"Choi","year":"2020","journal-title":"Blood Res"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723010734?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723010734?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:07:30Z","timestamp":1763003250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636723010734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2666636723010734"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2023.02.005","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unique Reduced-Intensity Conditioning Haploidentical Peripheral Blood Stem Cell Transplantation Protocol for Patients with Hematologic Malignancy","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2023.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}